Clinical Trial Update: A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the long-term safety, tolerability, and efficacy of Efgartigimod PH20 SC in adults with bullous pemphigoid has been terminated, with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bullous Pemphigoid

Drugs mentioned

• Efgartigimod PH20 SC (efgartigimod alfa)

Snippet

Sponsor: argenx | Conditions: Bullous Pemphigoid | Phase 3 | Status: TERMINATED | Results posted: 2026-02-25